WellPoint Clarinex Switch Petition Assertions Are “Troubling” – NCL
This article was originally published in The Tan Sheet
Executive Summary
An FDA-mandated OTC switch of Schering-Plough's Clarinex (desloratadine) would be "troubling" and would represent "a serious shift in agency policy," the National Consumers League states